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Abstract
Background: The local injection of novel cardioprotective study drugs prior to percutaneous coronary intervention
could cause embolisation of thrombus, resulting in increased reperfusion injury and subsequent infarct size. The aim of
this study was to assess the safety of the delivery of an intracoronary therapy delivered during primary percutaneous
coronary intervention for acute myocardial infarction prior to the re-establishment of thrombolysis in myocardial
infarction III flow.
Methods: One hundred sixty-seven patients with acute myocardial infarction successfully reperfused through primary
percutaneous coronary intervention and undergoing Cardiac MRI within the first week after reperfusion were studied.
Patients either underwent the delivery of an intracoronary agent (IMP or placebo) prior to balloon dilatation (n¼ 80) or
standard primary percutaneous coronary intervention procedure (n¼ 117).
Results: Baseline characteristics were similar between the two groups. There were a similar number of successful
procedures (IC IMP 75 (93.8%) vs. No IMP 114, (97.4%), p¼ 0.374), rates of no-reflow (IC IMP 1 (1.3%) vs. No IMP 2
(1.7%), p¼ 0.99) and levels of ST segment resolution (88.5% IC IMP vs. No IC IMP 87.0%, p¼ 0.669) between the two
groups. Similar levels of microvascular obstruction were seen between the two groups with a trend to reduced infarct
size, and improved ejection fractions in the IMP group. Lower MACE rates were seen in the IMP group.
Conclusion: The local intracoronary infusion of potential cardioprotective agents prior to the restoration of TIMI
flow in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction appears to
be safe and does not increase microvascular damage. This route should be considered when testing novel cardiopro-
tective agents.
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Introduction
Timely delivered primary percutaneous coronary inter-
vention (PCI) has become the favoured reperfusion
therapy for ST-elevation myocardial infarction
(STEMI) in the US and Europe.1 However, this inter-
ventional technique has not abolished the unpredictable
phenomenon of no-reflow, reperfusion injury and the
underappreciated, but potentially equally important,
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syndrome of microvascular obstruction (MVO).2 MVO
has been associated with adverse prognosis, adverse LV
remodeling and diminished recovery of LV function,
independently of infarct size.3,4
Compared with the systemic administration of intra-
venous pharmacotherapies, highly localized adminis-
tration of intracoronary pharmacotherapy may be
associated with a several-hundred-fold increase in the
local concentration of an agent in the epicardial artery/
microcirculation with associated beneficial effects.
However, despite the potential benefit of this technique,
there is limited evidence for the delivery of therapies
locally prior to balloon dilatation and restoration of
thrombolysis in myocardial infarction (TIMI) flow.
Potentially, infarct size may be increased as injection
of the study drugs prior to PCI could cause embolisa-
tion of thrombus to the microcirculation, resulting in
increased MVO, reperfusion injury and subsequent
infarct size. Several studies have opted to infuse novel
therapies such as adenosine after thrombus aspiration
to minimise the chances of this occurrence.5,6
The aim of this study was to assess the safety of the
delivery of intracoronary therapies delivered during pri-
mary PCI for AMI prior to the re-establishment of
TIMI III flow.
Methods
Between April 2008 and November 2012, 197 patients
with ST-segment elevation MI successfully reperfused
through primary percutaneous coronary intervention
(PCI) and undergoing CMR within the first week after
reperfusion were studied. All of these patients had been
consented into interventional clinical trials including
stem cell trial and pharmacological intervention trials
(REGENERATE- AMI (NCT00765453), NITRITE-
AMI (NCT01584453) and myocardial oedema in acute
myocardial infarction (AMI) (NCT00987259)). These
studies were approved by local ethics committee and
performed in accordance with the Declaration of
Helsinki (1996) and the principles of the International
Conference on Harmonization–Good Clinical Practice
(ICH-GCP) guidelines.
NITRITE-AMI was a double-blind, randomised,
single-centre, placebo-controlled trial to determine
whether the intra-coronary injection of sodium nitrite
reduces infarct size in patients with acute STEMI
undergoing primary PCI.7,8 After coronary angiog-
raphy, patients were randomised (1:1) to a high-dose
bolus injection of intra-coronary sodium nitrite
(1.8 mmol in 10mL of 0.9% NaCl) or placebo (10mL
of 0.9% NaCl) administered via an over the wire
(OTW) balloon just prior to balloon inflation. Both
REGENERATE-AMI (which recruited 100 patients
with patients presenting with anterior STEMI) and
myocardial oedema in AMI studies underwent standard
primary PCI for AMI with no administration of intra-
coronary therapy through an OTW. Use of adjunctive
therapies such as aspiration thrombectomy was at the
discretion of the operators in all three studies.
CMR imaging
Cardiac magnetic resonance (CMR) imaging was per-
formed on a 15 T Philips Achieva scanner with a cardiac
32-channel phased array coil. Balanced steady-state free
precession cine imaging was used to acquire 10–12 short
axis slices (8mm slice thickness, 2mm gap) with one slice
per breath-hold. Sequence parameters were 1.5 ms echo
time (TE), 3.1ms repetition time (TR), and acquired
voxel size was 1.8 1.86mm with a typical field of
view (FOV) of 360mm in the phase encode direction.
We acquired 45 phases with 25% phase sharing.
Parallel imaging (SENSE) was used with an acceleration
factor of 2.0.
Delayed enhancement images were acquired 10min
after injection of a dose of 02mmol/kg of gadoterate
meglumine (Dotarem) for late gadolinium enhancement.
A T1-weighted segmented inversion-recovery gradient
echo pulse sequence (TR 3.9 ms TE 1.9ms, flip angle
15, voxel size of 2 2mm, typical FOV 360mm) was
used to obtain 10–12 short axis slices (matched with
short-axis cine images) with one slice per breath-hold.
The inversion time was adjusted individually according
to a T1 scout sequence (Look-Locker). Images were
acquired every other heart beat with two signal averages.
Myocardial oedema was assessed using fat sup-
pressed T2-weighted triple inversion turbo spin echo
STIR (Short tau inversion recovery) imaging (TE
80ms, TR two heart beats, TSE factor 31, voxel size
1.8 1.8mm); 10–12 slices were obtained (8mm per
slice, 2mm gap matched to DE/cine slices) with one
slice per breath-hold. This sequence has previously
been used and validated for assessment of myocardial
oedema and MSI.9–11
Images were anonymised, batched and analysed in
blinded fashion by two experienced operators. Scar and
oedema volumes were calculated by manually drawing
endocardial and epicardial contours followed by semi-
automated selection of normal remote myocardium per
slice. Myocardial oedema was described as >2SD in
signal intensity from remote normal myocardium.
Infarct size was calculated using the full-width half
maximum method as previously described.12 In case
of discordance between operators, blinded review by a
level III accredited CMR reader was performed.
Analysis was performed using dedicated software
(CVI42, Circle Cardiovascular Imaging Inc., Calgary,
Alberta, Canada). Inter and intra-observer variability
was calculated.
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Statistical analyses
The study population was divided into 2two groups:
Intra-Coronary IMP (IC IMP) and no IMP. Primary
study end point was the myocardial salvage index on
CMR. Secondary endpoints included final TIMI
flow 2 on angiography, rate of ST-segment resolution
post primary PCI, the degree of myocardial hemor-
rhage (T2* measurement) and occurrence of MVO at
the first time point of within 48 h post-STEMI, and
parameters of left ventricular remodeling including left
ventricular end diastolic volume index (LVEDI),
left ventricular end systolic volume index (LVESI),
left ventricular stroke volume index (LVSVI), left ven-
tricular ejection fraction, and infarct size post STEMI.
Continuous data were expressed as mean standard
deviation and analyzed by the Student t test.
Categorical variables were reported as frequencies
and percentages and analyzed by the Chi-square or
Fisher exact test, as appropriate. All tests were two-
tailed, and statistical significance was accepted at
p< 0.05.
As this was a post trial comparison between RCTS, a
post hoc sample size was calculated for the between-
group comparison with regard to the primary endpoint
of myocardial salvage index. From the results of pub-
lished studies and this trial data, a sample size of 198,
with a mean MSI of 48 and a SD of 15% gives a stat-
istical power of 80% power, to reject the null hypothesis
of equal means between the two groups assuming no less
than 4% difference (two-tailed Student t test, 0.05).
Results
One hundred ninety-seven patients presenting with
AMI undergoing primary PCI were included in the
analysis. Patients either underwent the delivery of a
novel study IMP or placebo intracoronary prior to bal-
loon dilatation (n¼ 80) or standard primary PCI pro-
cedure (n¼ 117). The mean ages of patient were
56.4 11.2 years and 86% were male. Clinical and
angiographic characteristics of the population are
shown in Table 1. The two groups were similar with
regard to age, sex, LVEF and medical therapy; due to
the inclusion criteria of the individual clinical studies,
there were a greater number of left anterior descending
artery (LAD) occlusions in the non-IC IMP cohort.
CMR was performed at a median of three days
(range: 2–3 days) after primary PCI.
Procedural characteristics were similar between the
two groups with rates of thrombus aspiration catheters,
GPIIb/IIIa inhibitors and use of drug eluting stents.
Procedural outcomes
There were a similar number of successful procedures in
the two cohorts (IC IMP 75 (93.8%) vs. No IMP 114,





(n¼ 80) (n¼ 117) p
Age (yr) 56.98 12.18 56.20 10.18 0.6266
Sex (M/F) 67/13 103/14 0.3931
BMI (kg/m2) 27.28 5.15 26.75 3.71 0.4022
Ethnicity (Caucasian) (No. (%))
Medical history
Hypertension (No. (%)) 34 (42.5%) 38 (32.5%) 0.1530
Hypercholesterolemia (No. (%)) 28 (35.0%) 33 (28.2%) 0.3135
Diabetes mellitus (No. (%)) 6 (7.5%) 10 (8.5%) 0.7929
Active smoker (No. (%)) 16 (20.0%) 53 (45.3%) <0.0001
Previous MI (No. (%)) 0 (0.0%) 3 (2.6%) 0.1505
Previous PCI (No. (%)) 2 (5.0%) 2 (1.7%) 0.7010
Culprit vessel: <0.0001
LAD (No. (%)) 21 (26.3%) 105(89.7%)
LCx (No. (%)) 10 (12.5%) 3 (2.6%)
RCA (No. (%)) 49 (61.3%) 9 (7.7%)
Timings:
Chest pain to PCI (min) 189.34 72.03 206.1 81.5 0.330
LAD: left anterior descending artery; PCI: percutaneous coronary intervention.
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(97.4%), p¼ 0.374). Rates of no-reflow were similar
between the two groups (IC IMP 1 (1.3%) vs. No
IMP 2 (1.7%), p¼ 0.99). Levels of ST segment reso-
lution (>70% within 90min of the procedure) were
the same in the two groups (88.5% IC IMP vs. No
IC IMP 87.0%, p¼ 0.669).
CMR parameters
Acute LV volumes (p¼ 0.0034 for diastolic volumes
and p¼ 0.0023 for systolic volumes) were smaller and
LV ejection fractions were greater (p¼ 0.0327) in the
patients who received IC IMP compared to those
who received no IC IMP (Table 2). No differences
were seen in infarct size, AAR, or MSI (Figure 1)
between the two groups (Table 2). Rates of and
amounts of MVO were similar in the two groups
(Table 2 and Figure 2). MSI, rates of MVO and myo-
cardial haemorrhage were comparable between treat-
ment groups when patients were split into either LAD
or non-LAD infarcts. At six months after primary PCI,
higher ejection fractions were seen in the IC IMP group
compared to no IC IMP (55.3% vs. 51.3%, p¼ 0.012).
No differences in LV volumes, mass or infarct size were
seen (Table 2).
Inter-observer and intra-observer variability
Measurements of LV function, T2 AAR, MVO and LV
scar parameters were evaluated by interclass correlation
coefficient (ICC) with 95% CI. Inter-observer agree-
ment for LVEF, IS, MVO, AAR and MSI was excel-
lent, with ICCs of 0.992, 0.925, 0.968, 0.908 and 0.951,
respectively. Intra-observer agreement was also excel-
lent, with ICC of LVEF: 0.982, IS 0.980, MVO 0.991,
AAR 0.982, and MSI of 0.931.
Adverse events
One year after infarction, seven patients (8.75%) in the
IC IMP group suffered MACE (two hospitalisations
for heart failure, one recurrent myocardial infarction
and four unscheduled revascularizations) compared to
17 patients (14.5%) (1 mortality, 4 recurrent MI, 10
unscheduled revascularization, 2 hospitalisations for
heart failure) in the no IC IMP group (p¼ 0.1685)
(Figure 3).
Discussion
This study demonstrates that the local intracoronary
infusion of a novel cardioprotective agent prior to the
Table 2. Cardiac magnetic resonance data for study population.
IC IMP No IC IMP
(n¼ 68) (n¼ 117) p
Baseline CMR
LVEDVi 73.35 14.79 80.71 16.01 0.0034
LVESVi 25.93 11.82 42.08 12.86 0.0023
LVMi 60.59 11.48 60.47 12.60 0.9503
LVEF 51.43 9.59 48.28 9.54 0.0327
Infarct size (% LV) 18.31 8.59 19.59 9.48 0.7166
AAR 33.80 9.57 33.13 11.03 0.6842
MSI 48.38 15.76 47.72 22.94 0.8396
MVO
No. (%) 39 (57.35%) 70 (59.83%) 0.6603
Amount (median (IQR) 1 (0–5.13) 1 (0–5.8) 0.8648
6 month CMR
LVEDVi 78.72 17.72 84.07 19.91 0.0941
LVESVi 35.64 12.49 40.98 16.17 0.0321
LVMi 53.33 9.67 53.08 14.00 0.9075
LVEF 55.30 8.60 51.32 10.54 0.0120
Infarct size (% LV) 12.77 6.33 12.52 9.61 0.8595
Note: Values shown as mean (95% CI) unless otherwise stated.
LVEDVi: indexed left ventricle end-diastolic volume; LVESVi: indexed left ventricle end-systolic volume; LVMi:
indexed left ventricle mass; LVEF: left ventricle ejection fraction; AAR: area at risk; MSI: myocardial salvage index;
MVO: microvascular obstruction.
4 Journal of the Royal Society of Medicine Cardiovascular Disease 0(0)
restoration of TIMI flow in patients undergoing pri-
mary PCI for AMI appears to be safe and does not
increase microvascular injury compared to standard
therapy. Intracoronary therapies have been shown to
be safe in two previous published studies8,13 including
NITRITE-AMI when delivered prior to reperfusion in
the context of primary PCI; however, this is the first
study to have a control arm with no IC agent to dem-
onstrate no harmful effect on the microvasculature.
Concerns over distal embolization and increased micro-
vascular damage with the delivery of local intra-
coronary therapies prior to reperfusion have been
raised but this study shows when compared to standard
therapy (i.e no IC agent), there is no evidence of such
an effect.
In the NITRITE-AMI study,8 MVO was shown to
be reduced in patients treated with nitrite compared to
those who received placebo with the incidence of MVO
reduced by 20% and 35% in the nitrite-treated group
in the whole cohort and the TIMI flow<1 subgroup,
respectively. However, this comparison was between
two groups who both received an IC infusion prior to
reperfusion which itself may have increased the amount
of reperfusion injury and microvascular injury.
Figure 1. Assessment of myocardial salvage index (MSI) on
CMR. Amount of MSI on CMR is presented for 117 patients in
the no IMP (control) group and 68 patients in the IMP group.
There was no difference in the MSI as assessed by CMR between
the two groups (p¼ 0.8396). Significance evaluated using
unpaired t test and data shown as mean SEM.
CMR: cardiac MR.
Figure 2. Assessment of microvascular obstruction on CMR.
Amount of microvascular obstruction on CMR is presented for
117 patients in the no IMP (control) group and 68 patients in the
IMP group. There was no difference in the amount of micro-
vascular obstruction as assessed by CMR between the two
groups (p¼ 0.8648). Significance evaluated using unpaired t test
and data shown as mean SEM.
CMR: cardiac MR.
Figure 3. Kaplan–Meier curves showing cumulative probability
of major adverse cardiac events (MACE) after primary PCI
according to treatment group.
PCI: percutaneous coronary intervention.
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This study has demonstrated that compared to stand-
ard therapy this is not the case. It is worth noting that
factors that impact on MVO, such as comorbid condi-
tions and the use of antiplatelet and anticoagulant ther-
apy, were similar between the two treatment groups.
MVO has been implicated in worse clinical outcomes
due to poor myocardial perfusion despite epicardial
coronary artery revascularization.14
The timing of the cardio-protective strategy is crit-
ical in the design of clinical studies. The time window of
protection is quite narrow because the main part of
lethal reperfusion injury takes place within the first
minutes of reflow after prolonged ischemia. Protective
interventions must be applied either intravenously prior
to the opening of the culprit coronary artery or locally
at the onset of reperfusion.
Compared with the systemic administration of intra-
venous pharmacotherapies, the highly localized admin-
istration of intracoronary pharmacotherapy may be
associated with a several-hundred-fold increase in the
local concentration of an agent; however, despite
the potential benefit of this technique, there is limited
evidence for the delivery of therapies locally prior to
balloon dilatation and restoration of TIMI Flow.
Potentially infarct size may be increased as injection
of the study drugs prior to PCI could cause embolisa-
tion of thrombus and other particles to the microcircu-
lation, resulting in increased MVO, reperfusion
injury and subsequent infarct size. Several studies
have therefore adopted to infuse novel therapies to
reduce reperfusion injury after reperfusion (restored
with thrombus aspiration) to minimise the chances of
this occurrence.5,15,16 The importance of the state of the
microcirculation after primary PCI and its association
with outcomes is being increasingly recognised17 and
understood and this study demonstrating the safety
of local drugs administered prior to reperfusion is
important for the design of future studies aimed at
cardioprotection.
Limitations
This is a combination of several RCTS recruiting
patient population who have suffered STEMI and
underwent successful primary PCI. One of the studies
included in the analysis recruited only patients with
anterior infarcts due to occlusions of the LAD, which
may have lead to bias in the results.
Conclusion
The local intracoronary infusion of potential cardio-
protective agents prior to the restoration of TIMI
flow in patients undergoing primary PCI for AMI
appears to be safe and does not increase microvascular
damage. This route and the methodology described
here should be considered when testing novel cardio-
protective agents.
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